Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allison Richards

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with OutcomesMorganna Freeman-Keller, Youngchul Kim, Heather Cronin, et al.
Glia|March 19, 2019
Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficitsDorit Farfara, Emily Feierman, Allison Richards, et al.
Journal of Comparative Effectiveness Research|August 15, 2017
Stakeholders' views on data sharing in multicenter studiesKathleen M Mazor, Allison Richards, Mia Gallagher, et al.
Cancer Immunology Research|February 14, 2016
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after IpilimumabJeffrey Weber, Geoffrey Gibney, Ragini Kudchadkar, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 14, 2021
Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific FunctionJohn E Mullinax, MacLean Hall, Matthew Beatty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2019
BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T CellsCigdem Atay, Taekyoung Kwak, Sergio Lavilla-Alonso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2014
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanomaGeoffrey T Gibney, Ragini R Kudchadkar, Ronald C DeConti, et al.
Frontiers in Oncology|March 20, 2018
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic MelanomaJohn E Mullinax, MacLean Hall, Sangeetha Prabhakaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced MelanomaAhmad A Tarhini, Zeynep Eroglu, Islam Eljilany, et al.
Research Square|September 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialWungki Park, Catherine O'Connor, Joanne Chou, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with OutcomesMorganna Freeman-Keller, Youngchul Kim, Heather Cronin, et al.
Glia|March 19, 2019
Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficitsDorit Farfara, Emily Feierman, Allison Richards, et al.
Journal of Comparative Effectiveness Research|August 15, 2017
Stakeholders' views on data sharing in multicenter studiesKathleen M Mazor, Allison Richards, Mia Gallagher, et al.
Cancer Immunology Research|February 14, 2016
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after IpilimumabJeffrey Weber, Geoffrey Gibney, Ragini Kudchadkar, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 14, 2021
Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific FunctionJohn E Mullinax, MacLean Hall, Matthew Beatty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2019
BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T CellsCigdem Atay, Taekyoung Kwak, Sergio Lavilla-Alonso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2014
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanomaGeoffrey T Gibney, Ragini R Kudchadkar, Ronald C DeConti, et al.
Frontiers in Oncology|March 20, 2018
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic MelanomaJohn E Mullinax, MacLean Hall, Sangeetha Prabhakaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced MelanomaAhmad A Tarhini, Zeynep Eroglu, Islam Eljilany, et al.
Research Square|September 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialWungki Park, Catherine O'Connor, Joanne Chou, et al.
Pageof 1